Search

Life Science

US Therapeutic Plasma Exchange (TPE) Market

US Therapeutic Plasma Exchange (TPE) Market - By Components, By Solution, By Service, By Technology, By Application & Global Region - Market Size, Trends, Share & Forecast 2020-2025

Request Sample Request Discount
  • Status : Upcoming
  • Published on: Jan 2021
  • Report ID: KDMI-6897
  • Available Format: PDF/Execel/DOC
  • Delivery Time: 24-48 hrs

According to The American Heart Association, in 2018, nearly 92.1 million individuals in the U.S. suffered from cardiovascular diseases. There has also been a massive rise in the prevalence of various autoimmune disorders in the U.S in the recent years which has led to a surge in research and development activities in the region by the pre-existing and new pharma & biotech companies. A solution which has been emerging in the form of Therapeutic Plasma Exchange has proven to be substantial in treating various kinds of prevailing and rare illnesses in the region and also globally.

Therapeutic Plasma Exchange (TPE) is basically a procedure in which the blood of a patient is made to pass through an apheresis machine, where filtered plasma is removed and is re-infused with fresh red blood cells (RBC) together with replacement fluids, which includes albumin or plasma in patients. Diseases that are treated with the help of therapeutic plasma exchange include acute inflammatory demyelinating polyneuropathy (guillain-barré syndrome), chronic inflammatory demyelinating polyradiculoneuropathy, myasthenia gravis, and thrombotic thrombocytopenic purpura among others.

The U.S is expected to hold the largest share and lead the overall therapeutic plasma exchange systems market due to the increased availability of advanced technology and established healthcare infrastructures in the region. The market is also expected to grow at a more than healthy CAGR in the upcoming years.

MARKET DRIVERS:

The growth of this market is attributed towards major relying factors including; the growing prevalence of neurological and chronic diseases; increasing clinical response rate for therapeutic plasma exchange in Guillain-Barré syndrome, chronic inflammatory, demyelinating polyneuropathy, and myasthenia gravis, the growing prevalence of multiple sclerosis in the US, growing worldwide population living with numerous disease conditions, rapid and consistent technological progress in this sector in the future years etc.

Moreover, the rising adoption of this form of treatment for the purpose of treating many rare and also prevailing illnesses is likely to offer tremendous scope of growth for players in the US therapeutic plasma exchange market in the years to come.

Furthermore, the therapeutic plasma exchange is adopted  in the treatment of autoimmune, renal, hematological, and hematological diseases with suspected or known immune pathogenesis. Also, this process is being increasingly used in pediatric nephrology, which is likely to foster growth of the US therapeutic plasma exchange market over the years that are to follow in the near future.

More importantly, the Convalescent plasma therapy has been highly successful in treating infected patients with coronavirus lately.  The profound “cytokine storm” induced endotheliopathy and microthrombotic disease in patients with COVID-19 is said to lead to acute respiratory distress syndrome, sepsis, and multi-organ failure. Therapeutic plasma exchange (TPE) is the only known procedure to directly and rapidly decrease plasma viscosity, suggesting that TPE may improve patient outcomes in critically ill patients with COVID-19 by decreasing plasma viscosity and thereby enhancing blood flow. This is contributing massively in augmenting demand and the growth of the overall US TPE market.

However, high cost of apheresis devices and therapeutic plasma exchange procedures, lack of awareness about the TPE process, high installation cost of apheresis devices through a rental model, dearth of skilled professionals, and risks associated with therapeutic plasma exchange procedure are factors that are restraining the growth of this market.

US THERAPEUTIC PLASMA EXCHANGE MARKET SEGMENTATION:

By Product:

  • Consumables
  • Devices

By Technology:

  • Centrifugation
  • Membrane Separation

 By Indication:

  • Neurological Disorders
    • Guillain–Barré syndrome
    • Chronic inflammatory demyelinating polyneuropathy
    • Myasthenia gravis
    • Multiple sclerosis
    • PANDASa
  • Hematology Disorders
    • Thrombotic thrombocytopenic purpura
    • Atypical haemolytic uraemic syndrome
    • Hyperviscosity syndromes
    • Severe/symptomatic Cryoglobulinemia
  • Renal Disorders
    • Goodpasture’s syndrome
    • Wegener’s glomerulonephritis
    • Antibody-mediated renal transplant rejection
  • Metabolic Disorders
    • Familial hypercholesterolaemia (homozygous)
  • Autoimmune Disorders
  • Other Indications

By End User:

  • Blood Collection Centres & Blood Component Providers
  • Hospitals & Transfusion Centres
  • Other End Users

FEW KEY PLAYERS IN US THERAPEUTIC PLASMA EXCHANGE MARKET:

  • Terumo BCT Inc.
  • Haemonetics Corporation
  • Miltenyi Biotec
  • Medica S.p.A.
  • Medicap Clinic GmbH
  • Asahi Kasei Medical Co. Ltd.
  • Braun Melsungen AG
  • Cerus Corporation
  • Infomed
  • Fresenius Medical Care
  • Baxter International Inc.
  • Kawasumi Laboratories Inc.
  • Kaneka Corporation
  • Nikkiso Co. Ltd.
  • HemaCare Corporation
  • Other Players

RECENT DEVELOPMENTS:

In November 2020, Cerus Corporation announced that the US Food and Drug Administration (FDA) granted approval of the INTERCEPT Blood System for Cryoprecipitation. The system is used to produce Pathogen Reduced Cryoprecipitated Fibrinogen Complex for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency.

In December 2020, Spero Therapeutics Inc. a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant (MDR) bacterial infections, announced that its initiation of dosing in patients with nontuberculous mycobacterial pulmonary disease (NTM-PD) in its dose-ranging Phase 2a clinical trial of SPR720, Spero’s oral antimicrobial agent in development for the treatment of NTM-PD.

Timeline Considered for Analysis:

- 2019: Base Year

- 2020 to 2025: Forecast Period

Research Scope and Deliverables

Overview & Executive Summary

Market Drivers, Trends, Challenges and Opportunities

Market Size and Forecast Projections

Macroeconomic Indicators of US Impacting the Growth of the Market

Extensive Coverage of Industry Players including Recent Product Launches and Market Activities

Porter’s Five Force Analysis

Market Segmentation Analysis:

Industry report analyzes the US therapeutic plasma exchange market by the following segments:

  • Product
  • Technology
  • Indication
  • End User

Customization: We also offers customization’s in the industry report as per the company’s specific needs.

Key Questions Answered in the US Therapeutic Plasma Exchange Industry Report

  • What is the overall market size in 2019? What will be the market growth during the forecast period i.e. 2020-2025?
  • What are the factors driving the growth of the market?
  • Which sub-market will make the most significant contribution to the market?
  • What are the market opportunities for existing and entry-level players?
  • What are various long-term and short-term strategies adopted by the market players?

Custom Research Requirement? Questions to ask?

Get in touch

Custom Research requirement.

Go Up